Coexisting lung cancer and pulmonary tuberculosis (LC-PTB) is clinically challenging in diagnosis and treatment, and its mechanisms are unclear.
A study published in the journal iMetaMed aimed to explore its immune and molecular basis to identify diagnostic biomarkers.
We prospectively enrolled LC patients, LC-PTB patients, and controls.
Lymphocyte subsets were analysed by flow cytometry.
Key markers were identified through blood transcriptome sequencing and bioinformatics (differential expression, GSEA, GO/KEGG), and validated by RT-qPCR and immunohistochemistry.
Analysis included 138 subjects (50 controls, 50 LC, 38 LC-PTB).
Compared to LC alone, LC-PTB demonstrated significantly increased CD4+ T cells (p = 0.0064) and NK cells (p = 0.0447), with an elevated CD4/CD8 ratio.
HER2 Uncovered: From Low to Ultralow – Get the Low Down with Ben Dessauvagie & Gelareh Farshid
Transcriptome analysis identified 144 upregulated and 435 downregulated genes in LC-PTB versus controls, and 216 upregulated and 388 downregulated genes versus LC alone (|Fold Change| ≥ 2, p < 0.05).
Enrichment analysis revealed involvement of antigen presentation, oxidative phosphorylation, and nitrogen metabolism.
Six key genes (ANK2, EPB42, CA1, HBB, HBD, MYL4) were identified.
A four-gene model (CA1, HBD, MYL4, ANK2) discriminated LC-PTB from LC (AUC 0.940, 95% CI 0.846–1.000).
We provide the first immune-transcriptomic map of LC-PTB and a validated four-gene diagnostic signature ready for external evaluation.
Source: FAR Publishing Limited